Bionano Genomics (BNGO) to Release Earnings on Monday

Bionano Genomics (NASDAQ:BNGO) is expected to announce its Q4 2025 results after the market closes on Monday, March 23rd. Analysts expect the company to announce earnings of ($0.81) per share and revenue of $7.88 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 23, 2026 at 4:30 PM ET.

Bionano Genomics Stock Performance

Shares of Bionano Genomics stock opened at $1.13 on Friday. The stock’s fifty day moving average is $1.25 and its two-hundred day moving average is $1.70. The company has a market capitalization of $11.45 million, a PE ratio of -0.24 and a beta of 1.69. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.07. Bionano Genomics has a 52 week low of $1.06 and a 52 week high of $5.50.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Bionano Genomics in a research report on Monday, December 29th. HC Wainwright restated a “buy” rating and issued a $7.00 price target (down from $11.00) on shares of Bionano Genomics in a report on Monday, November 24th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.50.

Institutional Trading of Bionano Genomics

Several institutional investors and hedge funds have recently made changes to their positions in the company. DRW Securities LLC bought a new position in Bionano Genomics during the 4th quarter worth about $258,000. Geode Capital Management LLC raised its holdings in shares of Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares in the last quarter. Carret Asset Management LLC raised its holdings in shares of Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after purchasing an additional 19,100 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Bionano Genomics in the 4th quarter worth approximately $57,000. Finally, Jane Street Group LLC purchased a new stake in shares of Bionano Genomics in the 4th quarter worth approximately $34,000. 11.35% of the stock is currently owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.